effect of anti-glaucoma agents on intra ocular pressure Spikes after intravitreal bevacizumab injection in patients

Phase 3

Recruiting

• Conditions: Eye pressure of patients undergoing intravitreal injection of bevacizumab.; Glaucoma secondary to drugs; H40.6

• Registration Number: IRCT20230330057787N1
• Lead Sponsor: Zahedan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 16 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 108

Inclusion Criteria

1- Age more than 18 years
2- Informed and free consent to participate in the study
3- Patients who will have the first intra-boasizomat injection.

Exclusion Criteria

1- History of retinal surgery.
2- Rupture of the posterior capsule
3- High eye pressure or glaucoma
4- Use of topical medication (such as IOP-lowering medications and corticosteroids)
5- Active intraocular inflammation
6- Eye pathologies such as pterygium or corneal opacities that can affect the evaluation of study variables
7- Withdrawal from the study during research for any reason

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Intraocular pressure. Timepoint: The beginning of the study / one minute after injection / 30 minutes after injection / 24 hours after injection. Method of measurement: At the beginning of the study, 30 minutes after the injection and 24 hours after the injection, the intraocular pressure is measured with a Goldman tonometer and one minute after the injection with Tonopen.